The sources
Every GLOW peptide claim, traced to its study.
The full reference list behind this digest — peer-reviewed constituent studies for GHK-Cu, BPC-157 and thymosin beta-4, and the FDA primary sources for the regulatory page. Each entry links to PubMed, a DOI, or FDA.gov.
How to read these GLOW peptide references
These GLOW peptide references are the complete source list behind every quantitative claim on this site. They divide into two groups. The constituent literature — entries 1 through 11 — covers GHK-Cu, BPC-157 and thymosin beta-4 individually, because the GLOW blend itself has no published studies; the blend's evidence is assembled from these. The regulatory sources — entries 12 through 16 — are FDA primary documents and one law-firm analysis supporting the GLOW legal status and FDA 503A category page.
None of these studies tested the GLOW combination. Where a finding is topical, constituent-level, or uses full-length thymosin beta-4 rather than the TB-500 fragment, the body pages say so. The full citation list is below.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. ↗
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. ↗
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. ↗
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:118-122. ↗
- Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. ↗
- Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016;28(4):438-443. ↗
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (list entries for BPC-157; "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; and "GHK-Cu (for injectable routes of administration)"; effective 2023-09-29). ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 / Category 2 definitions; bulks-list and nomination framework; January 7, 2025 interim-policy change). ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (calendar listing BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List). ↗
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance landing page; finalized January 2025). ↗
- U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved but Are FDA-Regulated (basis for the cosmetic Copper Tripeptide-1 vs injectable-drug distinction). ↗